{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:55:15Z","timestamp":1768636515025,"version":"3.49.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cytogfr.2022.10.003","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T14:17:40Z","timestamp":1665670660000},"page":"13-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pharmacological therapies and drug development targeting SARS-CoV-2 infection"],"prefix":"10.1016","volume":"68","author":[{"given":"Yizhou","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limor","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaozhu","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Tao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Lazarovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cytogfr.2022.10.003_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7150\/ijbs.59272","article-title":"Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy","volume":"18","author":"Jiang","year":"2022","journal-title":"Int J. Biol. Sci."},{"issue":"7840","key":"10.1016\/j.cytogfr.2022.10.003_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-020-2739-1","article-title":"The coding capacity of SARS-CoV-2","volume":"589","author":"Finkel","year":"2021","journal-title":"Nature"},{"issue":"6965","key":"10.1016\/j.cytogfr.2022.10.003_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.cytogfr.2022.10.003_bib5","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1073\/pnas.0409465102","article-title":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry","volume":"102","author":"Hofmann","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120284","article-title":"ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors","volume":"293","author":"Portales","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib8","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5075","article-title":"Host cell entry mediators implicated in the cellular tropism of SARSCoV2, the pathophysiology of COVID19 and the identification of microRNAs that can modulate the expression of these mediators (Review)","volume":"49","author":"Katopodis","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"9371","key":"10.1016\/j.cytogfr.2022.10.003_bib9","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.cytogfr.2022.10.003_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"10229","key":"10.1016\/j.cytogfr.2022.10.003_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"Across speciality collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.10.003_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.10.003_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cytogfr.2022.10.003_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cytogfr.2022.10.003_bib16","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with covid-19","volume":"383","author":"Group","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib17","unstructured":"NIH, COVID-19 Treatment Guidelines. \u3008https:\/\/www.covid19treatmentguidelines.nih.gov\/\u3009, 2022 (Accessed 22. 07.09)."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib18","unstructured":"WHO, Therapeutics and COVID-19: living guideline. \u3008https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.4\u3009, 2022 (Accessed 22. 09.13)."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.02.002","article-title":"The Coronavirus pandemic - 2022: viruses, variants & vaccines","volume":"63","author":"Alexandridi","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib21","article-title":"The race for COVID-19 vaccines: the various types and their strengths and weaknesses","author":"Muhar","year":"2022","journal-title":"J. Pharm. Pract."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.10.003_bib22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"10223","key":"10.1016\/j.cytogfr.2022.10.003_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cytogfr.2022.10.003_bib24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jamacardio.2020.3557","article-title":"Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)","volume":"5","author":"Puntmann","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2022.102101","article-title":"An overview of the neurological aspects in COVID-19 infection","volume":"122","author":"Singh","year":"2022","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpeds.2020.05.006","article-title":"Clinical characteristics and outcomes of hospitalized and critically Ill Children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York City","volume":"223","author":"Chao","year":"2020","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.10.003_bib27","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jinf.2020.03.005","article-title":"Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients","volume":"80","author":"Liu","year":"2020","journal-title":"J. Infect."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.10.003_bib28","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses","volume":"53","author":"Zhou","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cytogfr.2022.10.003_bib29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.10.003_bib30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib31","article-title":"Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clim.2005.08.004","article-title":"C-reactive protein: ligands, receptors and role in inflammation","volume":"117","author":"Marnell","year":"2005","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib33","doi-asserted-by":"crossref","DOI":"10.5603\/ARM.a2022.0022","article-title":"Cardiotoxicity of azithromycin in COVID-19: an overall proportion meta-analysis","author":"Farmakis","year":"2022","journal-title":"Adv. Respir. Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00752-2021","article-title":"Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial","volume":"59","author":"Sivapalan","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.10.003_bib35","article-title":"Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis","volume":"48","author":"Batista","year":"2022","journal-title":"J. Bras. Pneumol."},{"issue":"10","key":"10.1016\/j.cytogfr.2022.10.003_bib36","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/aas.13941","article-title":"Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial","volume":"65","author":"Munch","year":"2021","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12874-022-01646-1","article-title":"Standard of care for COVID-19 in randomized clinical trials registered in trial registries and published in preprint servers and scholarly journals: a cross-sectional study","volume":"22","author":"Fidahic","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmicb.2015.00517","article-title":"Broad-spectrum antiviral agents","volume":"6","author":"Zhu","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108723","article-title":"Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products","volume":"227","author":"Kenig","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib40","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"5","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.cytogfr.2022.10.003_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/002221948702000903","article-title":"Epidemiology of pediatric closed head injury: incidence, clinical characteristics, and risk factors","volume":"20","author":"Goldstein","year":"1987","journal-title":"J. Learn. Disabil."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10010094","article-title":"Efficacy of high-dose polyclonal intravenous immunoglobulin in COVID-19: a systematic review","volume":"10","author":"Focosi","year":"2022","journal-title":"Vaccines"},{"issue":"18","key":"10.1016\/j.cytogfr.2022.10.003_bib43","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cmdc.202000368","article-title":"ACE2, the receptor that enables infection by SARS-CoV-2: biochemistry, structure, allostery and evaluation of the potential development of ACE2 modulators","volume":"15","author":"Gross","year":"2020","journal-title":"Chemmedchem"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.588618","article-title":"ACE2 in the era of SARS-CoV-2: controversies and novel perspectives","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Mol. Biosci."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.10.003_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir. Med"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib46","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3389\/fimmu.2020.01664","article-title":"Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach","volume":"11","author":"Choudhary","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.685308","article-title":"Drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2","volume":"12","author":"Tsegay","year":"2021","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-021-00619-y","article-title":"Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41422-020-00450-0","article-title":"Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.10.003_bib50","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ajh\/hpac001","article-title":"Effects of renin-angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: a meta-analysis of randomized controlled trials","volume":"35","author":"Yin","year":"2022","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12872-022-02565-1","article-title":"C.-C.C.C. Investigators, Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study","volume":"22","author":"Sato","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bcpt.13533","article-title":"Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.cytogfr.2022.10.003_bib53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17460441.2022.2029843","article-title":"The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19","volume":"17","author":"Mantzourani","year":"2022","journal-title":"Expert Opin. Drug Disco"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.10.003_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.cytogfr.2022.10.003_bib55","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","volume":"63","author":"Yu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.10.003_bib56","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.7150\/ijbs.59547","article-title":"Hydroxychloroquine\/chloroquine as therapeutics for COVID-19: truth under the mystery","volume":"17","author":"Chen","year":"2021","journal-title":"Int J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib58","unstructured":"FDA, Know Your Treatment Options for COVID-19. \u3008https:\/\/www.fda.gov\/consumers\/consumer-updates\/know-your-treatment-options-covid-19\u3009, 2022 (Accessed 22. 05.19)."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib59","article-title":"Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2","volume":"11","author":"Eweas","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101646","article-title":"A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease","volume":"35","author":"Hall","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173430","article-title":"In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2","volume":"886","author":"Deshpande","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1473-3099(20)30911-7","article-title":"The place for remdesivir in COVID-19 treatment","volume":"21","author":"Young","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"10339","key":"10.1016\/j.cytogfr.2022.10.003_bib63","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","author":"Consortium","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102396","article-title":"An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.10.003_bib65","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s40495-020-00226-5","article-title":"Pipeline pharmacological therapies in clinical trial for COVID-19 Pandemic: a recent update","volume":"6","author":"Kumari","year":"2020","journal-title":"Curr. Pharm. Rep."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.10.003_bib66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/01.CIR.74.4.901","article-title":"Phasic mitral blood flow and regional left ventricular dimensions: possible mechanism of active assist to ventricular filling","volume":"74","author":"Bertha","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cytogfr.2020.12.005","article-title":"The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved","volume":"58","author":"Coperchini","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib69","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-022-00987-z","article-title":"COVID-19 and corticosteroids: a narrative review","author":"El-Saber Batiha","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"6490","key":"10.1016\/j.cytogfr.2022.10.003_bib70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"C.H. June, Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cytogfr.2022.10.003_bib71","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.7150\/ijbs.58695","article-title":"Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers","volume":"17","author":"Yang","year":"2021","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cytogfr.2020.06.012","article-title":"A critical evaluation of glucocorticoids in the management of severe COVID-19","volume":"54","author":"Solinas","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"10","key":"10.1016\/j.cytogfr.2022.10.003_bib73","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/jcph.1936","article-title":"Corticosteroids in COVID-19: we should be mindful of their acute toxicities","volume":"61","author":"Karn","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690477","article-title":"The Many Faces of JAKs and STATs Within the COVID-19 Storm","volume":"12","author":"Grant","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2021.03.006","article-title":"COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1\/2 inhibitors in combination with interferon","volume":"60","author":"Hasselbalch","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.10.003_bib76","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT pathway inhibition and their implications in COVID-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad. Med."},{"issue":"7","key":"10.1016\/j.cytogfr.2022.10.003_bib77","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1080\/09546634.2018.1546043","article-title":"JAK-inhibitors in dermatology: current evidence and future applications","volume":"30","author":"Ciechanowicz","year":"2019","journal-title":"J. Dermatol. Treat."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.10.003_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"10223","key":"10.1016\/j.cytogfr.2022.10.003_bib79","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cytogfr.2022.10.003_bib80","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.cytogfr.2022.10.003_bib81","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/s41375-021-01266-6","article-title":"JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis","volume":"35","author":"Chen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib82","unstructured":"WHO, WHO recommends two new drugs to treat COVID-19. \u3008https:\/\/www.who.int\/news\/item\/14\u201301-2022-who-recommends-two-new-drugs-to-treat-covid-19\u3009, 2022 (Accessed 22. 05.19)."},{"issue":"8","key":"10.1016\/j.cytogfr.2022.10.003_bib83","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020306","article-title":"Janus kinase signaling pathway and its role in COVID-19 inflammatory, vascular, and thrombotic manifestations","volume":"11","author":"Ravid","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib85","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2665-9913(21)00314-3","article-title":"Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry","volume":"4","author":"Seror","year":"2022","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155544","article-title":"Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19","volume":"143","author":"Geng","year":"2021","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.10.003_bib87","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","author":"C.-C. group","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.610300","article-title":"Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases","volume":"11","author":"Carsetti","year":"2020","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2022.10.003_bib90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","article-title":"GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches","volume":"20","author":"Lang","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib91","article-title":"Targeting TNF-alpha for COVID-19: recent advanced and controversies","volume":"10","author":"Guo","year":"2022","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.10.003_bib92","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.16717","article-title":"Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments","volume":"55","author":"Kokkotis","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.cytogfr.2022.10.003_bib93","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41419-020-02748-8","article-title":"Apoptotic cell therapy for cytokine storm associated with acute severe sepsis","volume":"11","author":"Karbian","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198283","article-title":"Virology, C.-S.G.o.S.U. Infectious Diseases, Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19)","volume":"295","author":"Scagnolari","year":"2021","journal-title":"Virus Res"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cytogfr.2022.01.001","article-title":"Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review","volume":"63","author":"Lu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cytogfr.2021.12.001","article-title":"Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19","volume":"63","author":"Arico","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.10.003_bib97","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking CHanges in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"issue":"6538","key":"10.1016\/j.cytogfr.2022.10.003_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib99","first-page":"1","article-title":"Modeling SARS-CoV-2 spike\/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context","author":"Tragni","year":"2022","journal-title":"EPMA J."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib100","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib101","doi-asserted-by":"crossref","unstructured":"D. Mannar, J.W. Saville, X. Zhu, S.S. Srivastava, A.M. Berezuk, K.S. Tuttle, C. Marquez, I. Sekirov, S. Subramaniam, SARS-CoV-2 Omicron Variant: ACE2 Binding, Cryo-EM Structure of Spike Protein-ACE2 Complex and Antibody Evasion, bioRxiv (2021) 2021.12.19.473380.","DOI":"10.1101\/2021.12.19.473380"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib102","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2022.10.003_bib103","article-title":"Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib104","article-title":"SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19","volume":"6","author":"Hirsch","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib105","doi-asserted-by":"crossref","unstructured":"K. Bansal, S. Kumar, Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant, bioRxiv (2021) 2021.12.06.471389.","DOI":"10.1101\/2021.12.06.471389"},{"issue":"17","key":"10.1016\/j.cytogfr.2022.10.003_bib106","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1021\/jm060561m","article-title":"Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance","volume":"49","author":"Ghosh","year":"2006","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.cytogfr.2022.10.003_bib107","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib108","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab484","article-title":"Computational anti-COVID-19 drug design: progress and challenges","volume":"23","author":"Wang","year":"2022","journal-title":"Brief. Bioinform."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.10.003_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041676","article-title":"Advances in de Novo drug design: from conventional to machine learning methods","volume":"22","author":"Mouchlis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2022.10.003_bib110","article-title":"Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2","volume":"2","author":"Bajad","year":"2021","journal-title":"Curr. Res Pharm. Drug Disco"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.10.003_bib111","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013105","article-title":"A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2","volume":"13","author":"Simonis","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.10.003_bib112","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/13543776.2021.1861248","article-title":"Repurposing drugs for the management of COVID-19","volume":"31","author":"Cusinato","year":"2021","journal-title":"Expert Opin. Ther. Pat."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610122000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610122000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:02:58Z","timestamp":1761217378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610122000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":112,"alternative-id":["S1359610122000788"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2022.10.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological therapies and drug development targeting SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2022.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}